SC 13G/A

報告人名稱

上述人物的社會安全號碼或稅務人員識別號碼

EW醫療基金2號，有限合夥

如果是小組的成員，請勾選相應的選項

（a）☐（b）☒

公民身份或組織地點

特拉華州。

美國

證券交易委員會

華盛頓特區 20549

13G日程安排

根據1934年證券交易法

（修正案1）*

TELA Bio, Inc.

(發行人名稱)

普通股，每股面值0.001美元。

(證券類別)

872381108

(CUSIP號碼)

Martin P. Sutter

EW Healthcare Partners Fund 2，L.P.

21 Waterway Avenue，Suite 225

德蘭（Durango），德克薩斯州77380 董事長：理查德·卡吉爾（Richard A. Cargile）

(281) 364-1555

(收到通知和通信的人的姓名，地址和電話號碼)

2024年10月24日

(需要提交本聲明的事件日期)

請在適當的框內勾選適用的規則，提交該表格:

☐ 規則13d-1(b)。

☒ 規則 13d-1(c)。

☐ 規則 13d-1(d)。

*	本表剩餘頁面將用於提交人針對所述證券類別的首次填報，以及任何後續修改其中包含會影響之前提交頁面所提供披露信息的申報書。

本封面其餘部分所需的信息不得視爲《證券交易法案》第18條的目的而被「申報」，也不受該法案該條款的責任約束，但應受該法案的所有其他規定約束（但請參閱註釋）。

13G日程表

13G/A表格

說明

這是第1號修正協議書，附表13G("”），由一家特拉華州公司Sage Therapeutics, Inc.（以下簡稱“ 1)由EW Healthcare Partners Fund 2有限合夥，一個特拉華有限合夥履行EWHP2，EW Healthcare Partners Fund 2-A有限合夥 a Delaware limited partnership (“EWHP2-A”), EW Healthcare Partners Fund 2-GP, L.P., a Delaware limited partnership (“EWHP2 GP”), and EW Healthcare Partners Fund 2-UGP, LLC, 一個特拉華州有限責任公司（"EWHP2普通合夥人”和與EWHP2、EWHP2-A以及 EWHP2 GP一起，" EWHP投資者”和與EWHP2、EWHP2-A以及”或“公司報告人），並涉及普通股，每股面值$0.001（普通股”），即 TELA Bio, Inc.（「公司」處置）。此修改案件第1號的目的僅在於報告EWHP投資者對發行人普通股的受益所有權由於發行人承銷的公開發行而導致下降超過5％，該發行已於2024年10月24日結束。

事項1。

(a) 發行人名稱：TELA生物公司

(b) 發行人主要執行辦公室地址：1 Great Valley Parkway, Suite 24, Malvern, PA 19355。

條款2。

(a) 提交人姓名: 此修正案編號1由報告人共同提交。

(b) 主要業務辦公室地址: 每個報告人的主要業務地址均位於德克薩斯州伍德蘭市水路21號，225套間。

(d) 證券的頭銜和種類: 每股面值爲$0.001的普通股。

(e) CUSIP 編號: 872381108。

項目 3。如果此聲明是根據 §§ 文件的。根據240.13d-1(b)條款提交此聲明，請勾選報告人是否屬於以下人員：或。根據240.13d-2(b)條款提交此聲明，請勾選報告人是否屬於以下人員：或者（c），檢查提交申報的人是否爲以下之一：


(a)	☐	根據法案15條註冊的經紀商或證券交易商（15 U.S.C.78o）。

(b)	☐	法案3(a)(6)條規定的銀行（15 U.S.C. 78c）。

(c)	☐	本法案所定義的保險公司是指證券交易法案第3(a)(19)條（15 U.S.C. 78c）。

(d)	☐	根據1940年投資公司法案第8節（15 U.S.C. 80a 8）註冊的投資公司。

(e)	☐	根據投資顧問 ☐ 根據§240.13d-1(b)(1)(ii)(E)進行的投資顧問；

(f)	☐	符合240.13d-1(b)(1)(ii)(F)條款的員工福利計劃或捐贈基金。 240.13d-1(b)(1)(ii)(F)的方式；

(g)	☐	依據A的母公司或控制人。 240.13d-1(b)(1)(ii)(G);

(h)	☐	根據《聯邦存款保險法》第3（b）節（12 U.S.C. 1813）中定義的儲蓄協會；

(i)	☐	根據1940年投資公司法案第3(c)(14)節(15 U.S.C. 80a 3)，被排除在投資公司定義之外的教堂計劃;

(j)	☐	根據集團的要求， 240.13d-1(b)(1)(ii)(J)。

所有權。

提供有關發行人在項目1中確定的證券類別的總數和百分比的以下信息。⁽¹⁾

(a) Amount Beneficially Owned.

For EWHP2, 1,615,368 shares.

For EWHP2-A, 2,495,341 shares.

For EWHP2 GP, 4,110,709 shares.

For EWHP2 General Partner, 4,110,709 shares.

(b) Percent of Class.⁽²⁾

For EWHP2, 4.10%.

For EWHP2-A, 6.34%.

For EWHP2 GP, 10.44%.

For EWHP2 General Partner, 10.44%.

(i) Sole power to vote or to direct the vote:

For EWHP2, 1,615,368 shares.

For EWHP2-A, 2,495,341 shares.

For EWHP2 GP, 4,110,709 shares.

For EWHP2 General Partner, 4,110,709 shares.

(ii) Shared power to vote or to direct the vote:

For EWHP2, 0 shares.

For EWHP2-A, 0 shares.

For EWHP2 GP, 0 shares.

For EWHP2 General Partner, 0 shares.

(iii) Sole power to dispose or to direct the disposition of:

For EWHP2, 1,615,368 shares.

For EWHP2-A, 2,495,341 shares.

For EWHP2 GP, 4,110,709 shares.

For EWHP2 General Partner, 4,110,709 shares.

(iv) Shared power to dispose or to direct the disposition of:

For EWHP2, 0 shares.

For EWHP2-A, 0 shares.

For EWHP2 GP, 0 shares.

For EWHP2 General Partner, 0 shares.

(1)

The managers of EWHP2 General Partner are Martin P. Sutter, R. Scott Barry, Ronald Eastman and Petri Vainio (collectively, the “Managers”). The Managers may exercise voting and investment control over the shares of Common Stock only by majority action of the Managers. Each individual Manager disclaims beneficial ownership over the shares of Common Stock except to the extent of his respective pecuniary interest therein.

(2)

Based on an aggregate 39,383,798 shares of Common Stock outstanding as of October 24, 2024, which is based on (i) 24,713,798 shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report for the quarter ended June 30, 2024, filed with the U.S. Securities and Exchange Commission on August 13, 2024, and (ii) 14,670,000 shares of Common Stock issued in connection with the Issuer’s underwritten public offering, which closed on October 24, 2024.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Date: October 28, 2024


EW HEALTHCARE PARTNERS FUND 2, L.P.

By:	/s/ Martin P. Sutter
	Name:	Martin P. Sutter
	Title:	Managing Director

EW HEALTHCARE PARTNERS FUND 2-A, L.P.

By:	/s/ Martin P. Sutter
	Name:	Martin P. Sutter
	Title:	Managing Director

EW HEALTHCARE PARTNERS FUND 2-UGP, LLC

By:	/s/ Martin P. Sutter
	Name:	Martin P. Sutter
	Title:	Managing Director

EW HEALTHCARE PARTNERS FUND 2 GP, L.P.

By:	/s/ Martin P. Sutter
	Name:	Martin P. Sutter
	Title:	Managing Director

JOINT FILING AGREEMENT

Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Common Stock of TELA Bio, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G/A will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them, and (iii) the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934 apply to each of them. This agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13G/A as to any of the undersigned upon such person giving written notice thereof to each of the other persons signature hereto, at the principal office thereof.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Date: October 28, 2024


EW HEALTHCARE PARTNERS FUND 2, L.P.

By:	/s/ Martin P. Sutter
	Name:	Martin P. Sutter
	Title:	Managing Director

EW HEALTHCARE PARTNERS FUND 2-A, L.P.

By:	/s/ Martin P. Sutter
	Name:	Martin P. Sutter
	Title:	Managing Director

EW HEALTHCARE PARTNERS FUND 2-UGP, LLC

By:	/s/ Martin P. Sutter
	Name:	Martin P. Sutter
	Title:	Managing Director

EW HEALTHCARE PARTNERS FUND 2 GP, L.P.

By:	/s/ Martin P. Sutter
	Name:	Martin P. Sutter
	Title:	Managing Director